biostudies-literatureUnknown66Takahashi HThe consumption of Jerusalem artichoke has multiple beneficial effects against diabetes and obesity. The aim of this study was to determine the effect of a single administration of Jerusalem artichoke tubers on postprandial glycemia and the concentrations of incretin hormones in humans. Grated Jerusalem artichoke was administered prior to a meal (Trial 1; white rice for prediabetic participants, n = 10). Dose-dependent effect of Jerusalem artichoke (Trial 2; white rice for prediabetic participants, n = 4) and effect prior to the fat-rich meal were also investigated (Trial 3; healthy participants, n = 5) in this pilot study. Circulating glucose, insulin, triglyceride, glucagon, active glucagon-like peptide-1 (GLP-1), and active glucose-dependent insulinotropic polypeptide (GIP) concentratioFood & nutrition researchhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC8985572biostudies-literatureAdministration of Jerusalem artichoke reduces the postprandial plasma glucose and glucose-dependent insulinotropic polypeptide (GIP) concentrations in humans.PMC8985572Tomiga YYamanouchi HMatsumoto YInoue KMiyahara MAnzai KMatsuda YIba YMori HNakajima AWatanabe KTanaka KYada TTakahashi HfalseAdministration of Jerusalem artichoke reduces the postprandial plasma glucose and glucose-dependent insulinotropic polypeptide (GIP) concentrations in humans.The consumption of Jerusalem artichoke has multiple beneficial effects against diabetes and obesity. The aim of this study was to determine the effect of a single administration of Jerusalem artichoke tubers on postprandial glycemia and the concentrations of incretin hormones in humans. Grated Jerusalem artichoke was administered prior to a meal (Trial 1; white rice for prediabetic participants, n = 10). Dose-dependent effect of Jerusalem artichoke (Trial 2; white rice for prediabetic participants, n = 4) and effect prior to the fat-rich meal were also investigated (Trial 3; healthy participants, n = 5) in this pilot study. Circulating glucose, insulin, triglyceride, glucagon, active glucagon-like peptide-1 (GLP-1), and active glucose-dependent insulinotropic polypeptide (GIP) concentratio2022-01-01T00:00:00Z20222025-04-18T22:59:26.13Z2025-04-07T10:41:28.684ZS-EPMC89855723544093610.29219/fnr.v66.7870